PremiumCompany AnnouncementsArcellx Announces Positive Phase 2 Study Results Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel Arcellx Inc.: Strong Financial Position and Promising Phase 2 Study Outcomes Drive Buy Rating PremiumRatingsPromising Potential of Arcellx Inc’s Anito-cel Program Drives Buy Rating Arcellx’s Promising Trial Results and Strategic Partnerships Justify Buy Rating with $121 Target Arcellx Inc Announces Board Changes for Strategic Growth PremiumRatingsArcellx Inc’s Anito-cel Therapy: Promising Clinical Results and Strategic Partnerships Support Buy Rating Arcellx Inc’s Anito-cel: Promising Performance and Positive Outlook with Buy Rating Arcellx reports FY24 EPS ($2.00), consensus ($1.50) 
